2026-06-27T11:06:05Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1307352026-01-22T01:27:18Zcom_20.500.14352_14col_20.500.14352_15

Salazar de Pablo, Gonzalo Moreno Ruiz, María del Carmen Arango López, Celso Parellada Redondo, María José 2026-01-21T13:25:01Z 2026-01-21T13:25:01Z 2023-02-01 Salazar de Pablo, G., Pastor Jordá, C., Vaquerizo-Serrano, J., Moreno, C., Cabras, A., Arango, C., Hernández, P., Veenstra-VanderWeele, J., Simonoff, E., Fusar-Poli, P., Santosh, P., Cortese, S., & Parellada, M. (2023). Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response. Journal of the American Academy of Child and Adolescent Psychiatry, 62(2), 151–168. https://doi.org/10.1016/j.jaac.2022.03.033 0890-8567 10.1016/j.jaac.2022.03.033 https://hdl.handle.net/20.500.14352/130735 1527-5418 https://doi.org/10.1016/j.jaac.2022.03.033 35470032 https://linkinghub.elsevier.com/retrieve/pii/S0890-8567(22)00198-8 https://pubmed.ncbi.nlm.nih.gov/35470032/ Objective: Emotional dysregulation and irritability are common in individuals with autism spectrum disorder (ASD). We conducted the first meta-analysis assessing the efficacy of a broad range of pharmacological interventions for emotional dysregulation and irritability in ASD and predictors of response. Method: Following a preregistered protocol (PROSPERO: CRD42021235779), we systematically searched multiple databases until January 1, 2021. We included placebo-controlled randomized controlled trials (RCTs) and evaluated the efficacy of pharmacological interventions and predictors of response for emotional dysregulation and irritability. We assessed heterogeneity using Q statistics and publication bias. We conducted subanalyses and meta-regressions to identify predictors of response. The primary effect size was the standardized mean difference. Quality of studies was assessed using the Cochrane Risk of Bias Tool (RoB2). Results: A total of 2,856 individuals with ASD in 45 studies were included, among which 26.7% of RCTs had a high risk of bias. Compared to placebo, antipsychotics (standardized mean difference = 1.028, 95% CI = 0.824-1.232) and medications used to treat attention-deficit/hyperactivity disorder (ADHD) (0.471, 0.061-0.881) were significantly better than placebo in improving emotional dysregulation and irritability, whereas evidence of efficacy was not found for other drug classes (p > .05). Within individual medications, evidence of efficacy was found for aripiprazole (1.179, 0.838-1.520) and risperidone (1.074, 0.818-1.331). Increased rates of comorbid epilepsy (β = -0.049, p = .026) were associated with a lower efficacy. Conclusion: Some pharmacological interventions (particularly risperidone and aripiprazole) have proved efficacy for short-term treatment of emotional dysregulation and irritability in ASD and should be considered within a multimodal treatment plan, taking into account also the tolerability profile and families' preferences. eng http://creativecommons.org/licenses/by/4.0/ open access Attribution 4.0 International Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response journal article